Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer

These findings are in-line with safety data for bevacizumab plus paclitaxel or capecitabine, reported in previous phase III trials.